## Open Peer Review on Qeios

## Depatuxizumab Mafodotin

National Cancer Institute

## Source

National Cancer Institute. <u>Depatuxizumab Mafodotin</u>. NCI Thesaurus. Code C105612.

An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.